Invitae

Only three out of 10 sequencing workflows detected all variants in a synthetic reference sample, according to a study presented at ACMG.

The decline matched the struggles of the broader stock market, though bright spots could be found with GenMark, Quidel, and NanoString all having good months.

The firm increased the number of shares it was offering after its stock price fell sharply this week.

JP Morgan Securities and Cowen and Company are the joint book-running managers for the offering, while William Blair is the lead manager.

As part of Invitae's network, patients can build datasets tracking their experiences with rare conditions and make the deidentified data available for research.

Under the collaboration, Invitae will gain access to Kew's 435-gene tumor profiling NGS panel and proprietary bioinformatics software.

The loan can be funded at Invitae's option during the second quarter of 2018 and will provide flexibility as the firm grows its genome network.

Invitae reported $25.4 million in fourth quarter revenues compared to $9.2 million in Q4 2016, beating the consensus Wall Street estimate.

The Index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, and reversed the 3 percent loss it saw in December.